

# Press Release

Regulated information

## DISCLOSURE OF ACQUISITION OF TREASURY SHARES

Waregem (Belgium) / Rotterdam (the Netherlands)<sup>1</sup>, 5 April 2013 – Arseus discloses the information with respect to the acquisition of treasury shares required under Article 207 of the Royal Decree of 30 January 2001 implementing the Belgian Company Code.

Arseus today announces that it acquired 1,250 treasury shares on NYSE Euronext Brussels on 28 March 2013 (through an intermediate, acting with a discretionary mandate).

Acquisition date	Number of shares	Average price	Lowest price	Highest price	Amount
28 March 2013	1,250	€ 20.3965	€ 20.34	€ 20.47	€ 25,496

In addition Arseus acquired 13,000 treasury shares via a block trade on 28 March 2013.

Acquisition date	Block	Price	Amount
28 March 2013	13,000	€ 20.4700	€ 266,110

The Extraordinary Shareholders' Meeting held on 16 June 2009 renewed the authorisation of the Board of Directors to acquire treasury shares.

Prior to the transactions, Arseus already held 960,296 treasury shares. As a result of the transactions referred to above, Arseus now holds 974,546 treasury shares, representing 3.12% of the total number of shares outstanding.

*In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.*

---

<sup>1</sup> This press release was sent out by Arseus NV and Arseus BV.

**For more information:**

Constantijn van Rietschoten  
Director of Corporate Communications  
+31 88 33 11 222 (Office)  
+31 6 53 69 15 85 (Mobile)  
[constantijn.van.rietschoten@arseus.com](mailto:constantijn.van.rietschoten@arseus.com)

**Arseus profile**

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in 29 countries in Europe, North America, South America, Asia, Australia and Africa. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.